Thrombomodulin overexpression to limit neointima formation

Circulation

Volumn 102, Issue 3, 2000, Pages 332-337

  Waugh, J M ^a,b   Li Hawkins, J ^a,c   Yuksel, E ^a   Kuo, M D ^b   Cifra, P N ^a   Hilfiker, P R ^b   Geske, R ^a   Chawla, M ^d   Thomas, J ^d   Shenaq, S M ^a   Dake, M D ^b   Woo, Savio L C ^a,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Extracellular matrix; Gene therapy; Inflammation; Thrombosis; Viruses

Indexed keywords

THROMBOMODULIN;

ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON DILATATION; CORRELATION FUNCTION; GENE OVEREXPRESSION; GENE THERAPY; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS;

EID: 0034682607     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.3.332     Document Type: Article

References (46)

1. Cardif JC, Cote G, Lesperance J. et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997; 337:365-372.
2. Zoldhelyi P, McNatt J, Xu XM, et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 1996; 93:10-17.
3. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994;265:781-784.
4. Violaris AG, Melkert R, Herrman JR, et al. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty. Circulation. 1994;93:889-897.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med. 1994;330:956-961.
6. Trejo J, Connoly AJ, Coughlin SR. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. J Biol Chem. 1996;271: 21536-21541.
7. Walters TK, Gorog DA, Wood RFM. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process. J Vasc Res. 1994;31: 173-177.
8. Molino M, Bainton DF, Hoxie JA, et al. Thrombin receptors on human platelets. J Biol Chem. 1997;272:6011-6017.
9. Garg UC, Hassid A. Nitric oxide (NO) generating vasodilators and 8-bromo-cyclic GMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1974-1977.
10. Ross R. Growth regulatory mechanisms and formation of the lesions of atherosclerosis. Ann N Y Acad Sci. 1995;748:1-6.
11. Holifield B, Helgason T, Jamelka S, et al. Differentiated vascular myocytes: are they involved in neointimal formation? J Clin Invest. 1996;97: 814-825.
12. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 1995;92:3041-3050.
13. Marks DS, Vita JA, Folts JD, et al. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest. 1995;96:2630-2638.
14. Leopold JA, Loscalzo J. Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Coron Artery Dis. 1995;6:923-929.
15. Ye J, Esmon CT, Johnson AE. The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem. 1993;268: 2373-2379.
16. Bourin MC, Boffa MC, Bjork I, et al. Functional domains of rabbit thrombomodulin. Proc Natl Acad Sci U S A. 1986;83:5924-5928.
17. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem. 1982;257:859-864.
18. Esmon NL, Carrol RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem. 1983;258:12238-12242.
19. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45 year old man presenting with thromboembolic disease. Blood. 1995;85:330-336.
20. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;79:124-130.
21. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984;310:559-562.
22. Healy AM, Rayburn HB, Rosenberg RD, et al. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A. 1995;92:850-854.
23. Waugh JM, Yuksel E, Li J, et al. Gene therapy to promote thromboresistance: local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res. 1999;84:84-92.
24. Waugh JM, Kattash M, Li J, et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci U S A. 1999;96:1065-1070.
25. Moussa I, DiMario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12.
26. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
27. Li DY, Brooke B, Davis EC, et al. Elastin is an essential determinant of arterial morphogenesis. Nature. 1998;393:276-280.
28. Koyama H, Raines EW, Bornfeldt KE, et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 1996;87:1069-1078.
29. Simon DI, Ezratty AM, Francis SA, et al. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/ CD18): a nonplasmin fibrinolytic pathway. Blood. 1993;82:2414-2422.
30. Strauss BH, Robinson R, Batchelor WB, et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res. 1996;79:541-550.
31. Zempo N, Koyama N, Kenagy RD, et al. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28-33.
32. Yang Y, Nunes F, Berencsi K, et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407-4411.
33. Newman KD, Dunn PF, Owens JW, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995; 96:2955-2965.
34. Shankar R, de la Motte CA, Poptic EJ, et al. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem. 1994;269:13936-13941.
35. Rabiet MJ, Plantier JL, Dejana E. Thrombin-induced endothelial dysfunction. Br Med Bull. 1994;50:936-945.
36. Esmon CT, Fukodome K. Cellular regulation of the protein C pathway. Semin Cell Biol. 1995;6:259-268.
37. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095-4103.
38. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-399.
39. Libby P, Galis ZS. Cytokines regulate genes involved in atherosclerosis. Ann N Y Acad Sci. 1995;748:158-170.
40. Fuster V, Badimon JJ, Chesebro JH, et al. Plaque rupture, thrombosis, and therapeutic implications. Haemostasis. 1996;26(suppl 4):269-284.
41. Hansson GK, Jonasson L, Holm J, et al. Gamma interferon regulates vascular smooth muscle proliferation and Ia expression in vivo and in vitro. Circ Res. 1988;63:712-719.
42. Hansson GK, Hellstrand M, Rymo L, et al. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha smooth muscle actin in arterial smooth muscle cells. J Exp Med. 1989;170: 1595-1608.
43. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle hypertrophy versus hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90:456-461.
44. Tardif JC, Cote G, Lesperance J, et al, for the Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997;337:365-372.
45. Furukawa Y, Matsumori A, Ohashi N, et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999;84:306-314.
46. Rubin P, Williams JP, Riggs PN, et al. Cellular and molecular mechanisms of radiation inhibition of restenosis, I: role of the macrophage and platelet-derived growth factor. Int J Radiat Oncol Biol Phys. 1998;40: 929-941.